告别普涨，哪些创新药企“真金不怕火炼”

Core Viewpoint - The innovative drug sector is expected to experience a resurgence in 2025, transitioning from a broad market rally to a focus on select stocks driven by global clinical data, overseas commercialization, and domestic profitability turning points [1] Group 1: Market Performance - In 2025, the A-share innovative drug index saw an annual increase of nearly 20%, while the H-share index rose by 66.52%. The first half of the year recorded increases of approximately 17% for A-shares and 58% for H-shares, with the second half showing more modest gains of about 3% and 9% respectively [1] - The A-share billion-dollar club includes companies like BeiGene (市值4190.64亿元), Hengrui Medicine (市值3994.27亿元), and Baillie Gifford (市值1332.18亿元), while the H-share club includes Hengrui Medicine (市值4729.34亿元), BeiGene (市值3191亿元), and others [2] Group 2: Company Dynamics - Companies in the billion-dollar club are valued based on "pipeline value + BD monetization + global sales peak." Capital markets are comparing these firms to global leaders, elevating them from "First-in-class" to "Best-in-class" [3] - In 2025, domestic innovative drug license-out transactions totaled 83, amounting to $84.5 billion, surpassing the total of over $60 billion for 2024. Hengrui Medicine's international deals included partners like GSK and Merck, with upfront payments totaling $765 million [3] Group 3: Market Challenges - Some companies that previously entered the billion-dollar club, such as Kintor Pharmaceutical and China National Pharmaceutical Group, have fallen below the threshold due to systemic valuation corrections and stricter FDA approval standards [4] - The market has become desensitized to BD transactions, as evidenced by the stock price drop of Innovent Biologics following a $11.4 billion collaboration announcement, indicating a tightening of valuation expectations [4] Group 4: Capital Operations - As the innovative drug market heats up in 2025, companies are initiating new capital operations, including acquisitions and cross-border listings. For instance, China National Pharmaceutical Group acquired Lixian Pharmaceuticals for approximately $500 million [5] - Baillie Gifford raised 3.764 billion yuan through a private placement in the A-share market, while also applying for an IPO in Hong Kong [5] Group 5: Small-cap Stocks - The top three performing innovative drug stocks in A-shares for 2025 were Shuyou Pharmaceutical (涨幅488%), Yipinhong (涨幅370%), and Yifang Biotechnology (涨幅235%). In H-shares, the top performers were Beihai Kangcheng (涨幅1824%), Heber Pharmaceuticals (涨幅553%), and Sanofi (涨幅311.18%) [7] - These stocks have core products that received high recognition, with clinical pipelines achieving significant breakthroughs, such as Shuyou's STSP-0601 and Beihai Kangcheng's Selinexor [7] Group 6: Future Outlook - The innovative drug sector is expected to enter a "hardcore alpha" phase in 2026, focusing on companies that can deliver genuine clinical data, achieve overseas commercialization, and demonstrate domestic profitability [10] - The emphasis will shift from broad market rallies to specific companies that can prove their clinical trial results and secure sales milestones, with a focus on high-demand areas like dual antibodies and ADCs [11][12]